Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor originally developed for glycemic control in type 2 diabetes, has demonstrated promising hepatoprotective effects in both experimental and clinical studies [10,11,12,13,14,15,16,17,18,19]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.